TY - JOUR
T1 - Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion
T2 - Insights From the NCDR LAAO Registry
AU - Alkhouli, Mohamad
AU - Du, Chengan
AU - Killu, Ammar
AU - Simard, Trevor
AU - Noseworthy, Peter A.
AU - Friedman, Paul A.
AU - Curtis, Jeptha P.
AU - Freeman, James V.
AU - Holmes, David R.
N1 - Funding Information:
Dr Alkhouli is on the advisory board of Boston Scientific. Dr Freeman has received grants from the National Heart, Lung, and Blood Institute and the American College of Cardiology NCDR during the conduct of the study; and has received personal fees from Boston Scientific, Medtronic, Janssen Pharmaceuticals, and Biosense Webster outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
The study was funded by a grant from Boston Scientific; the sponsor had no role in the design of the study or the interpretation of the data.
Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/6
Y1 - 2022/6
N2 - Background: Data on the impact of residual peri-device leak after left atrial appendage occlusion (LAAO) are limited. Objectives: The goal of this study was to explore the association of peri-device leak with adverse clinical events. Methods: The National Cardiovascular Data Registry LAAO Registry was queried to identify patients undergoing LAAO between January 1, 2016, and December 31, 2019. Patients were classified according to leak size on echocardiography at 45 ± 14 days (0 mm, no leak; >0-5 mm, small leak; and >5 mm, large leak). Results: A total of 51,333 patients were included, of whom 37,696 (73.4%) had no leak, 13,258 (25.8%) had small leaks, and 379 (0.7%) had large leaks. The proportion of patients on warfarin at 45 days was higher in the large vs small or no leak cohorts (44.9% vs 34.4% and 32.4%, respectively; P < 0.001). At 6 and 12 months, anticoagulant utilization decreased but remained more frequent in patients with large leaks. Thromboembolic and bleeding events were uncommon in all groups. However, compared with patients with no leak, those with small leaks had slightly higher odds of stroke/transient ischemic attack/systemic embolization (adjusted HR: 1.152; 95% CI: 1.025-1.294), major bleeding (HR: 1.11; 95% CI: 1.029-1.120), and any major adverse events (HR: 1.102; 95% CI: 1.048-1.160). There were no significant differences in adverse events between patients with large leaks and patients with small or no leaks. Conclusions: Small (>0-5 mm) leaks after LAAO were associated with a modestly higher incidence of thromboembolic and bleeding events; large leaks (>5 mm) were not associated with adverse events, although higher proportions of these patients were maintained on anticoagulation. Newer devices with improved seal might mitigate the events associated with residual leaks.
AB - Background: Data on the impact of residual peri-device leak after left atrial appendage occlusion (LAAO) are limited. Objectives: The goal of this study was to explore the association of peri-device leak with adverse clinical events. Methods: The National Cardiovascular Data Registry LAAO Registry was queried to identify patients undergoing LAAO between January 1, 2016, and December 31, 2019. Patients were classified according to leak size on echocardiography at 45 ± 14 days (0 mm, no leak; >0-5 mm, small leak; and >5 mm, large leak). Results: A total of 51,333 patients were included, of whom 37,696 (73.4%) had no leak, 13,258 (25.8%) had small leaks, and 379 (0.7%) had large leaks. The proportion of patients on warfarin at 45 days was higher in the large vs small or no leak cohorts (44.9% vs 34.4% and 32.4%, respectively; P < 0.001). At 6 and 12 months, anticoagulant utilization decreased but remained more frequent in patients with large leaks. Thromboembolic and bleeding events were uncommon in all groups. However, compared with patients with no leak, those with small leaks had slightly higher odds of stroke/transient ischemic attack/systemic embolization (adjusted HR: 1.152; 95% CI: 1.025-1.294), major bleeding (HR: 1.11; 95% CI: 1.029-1.120), and any major adverse events (HR: 1.102; 95% CI: 1.048-1.160). There were no significant differences in adverse events between patients with large leaks and patients with small or no leaks. Conclusions: Small (>0-5 mm) leaks after LAAO were associated with a modestly higher incidence of thromboembolic and bleeding events; large leaks (>5 mm) were not associated with adverse events, although higher proportions of these patients were maintained on anticoagulation. Newer devices with improved seal might mitigate the events associated with residual leaks.
KW - atrial fibrillation
KW - ischemic stroke
KW - left atrial appendage
KW - peri-device leak
UR - http://www.scopus.com/inward/record.url?scp=85131319011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131319011&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2022.03.001
DO - 10.1016/j.jacep.2022.03.001
M3 - Article
C2 - 35387751
AN - SCOPUS:85131319011
SN - 2405-5018
VL - 8
SP - 766
EP - 778
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 6
ER -